CellOriginBeyond's analysis on CellOrigin2026-07-31 — CellOrigin’s reveal of two solid‑tumor CAR‑cell candidates and a Walvax partnership signals accelerated clinical progress and potential commercialization in the competitive immuno‑oncology arenaBrowse the full archive →